FDA Expands HT-001 Trial to Include Cancers With EGFR-Associated Toxicities
January 18th 2024Following clearance from the FDA, Hoth Therapeutics is carrying out a clinical trial as part of its open investigational new drug program for HT-001 in cancers undergoing toxicities from EGFR inhibition.
Read More
Phase 1/2 Study of STX-721 Doses First Patient With EGFR Exon 20+ NSCLC
October 11th 2023A first-in-human trial is assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of STX-721 as a monotherapy for patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.
Read More